Abstract
Patients with metastatic EGFR-mutated NSCLC who have progressed on osimertinib have limited treatment options. Dual EGFR blockade with HER2 blockade has been shown to have complete and long-term reversal of osimertinib resistance in preclinical models.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
